94 related articles for article (PubMed ID: 20705656)
21. Sorafenib-induced hepatic encephalopathy.
Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
[No Abstract] [Full Text] [Related]
22. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
Sieg M; Hartmann M; Settmacher U; Arefian H
BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma treated with sorafenib.
Han G; Zhao Y; Qi X; Fan D
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1347-8; discussion 1348. PubMed ID: 22085376
[No Abstract] [Full Text] [Related]
24. Sorafenib for advanced-stage hepatocellular carcinoma.
Tomuleasa C; Cristea V; Irimie A
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):346-7. PubMed ID: 22266833
[No Abstract] [Full Text] [Related]
25. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
Farinati F; Giacomin A; Vanin V
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1639-40; author reply 1641-2. PubMed ID: 22071597
[No Abstract] [Full Text] [Related]
26. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Shlomai A; Leshno M; Goldstein DA
PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
[TBL] [Abstract][Full Text] [Related]
27. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M
Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315
[TBL] [Abstract][Full Text] [Related]
28. Novel molecular therapies in hepatocellular carcinoma.
Faivre S; Bouattour M; Raymond E
Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
[TBL] [Abstract][Full Text] [Related]
29. Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
Wu SS; Yen HH; Chung CY
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):566-7. PubMed ID: 18555670
[No Abstract] [Full Text] [Related]
30. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
34. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
[TBL] [Abstract][Full Text] [Related]
35. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
[TBL] [Abstract][Full Text] [Related]
36. Drug therapy: sorafenib.
Finn RS
Hepatology; 2010 May; 51(5):1843-9. PubMed ID: 20432260
[No Abstract] [Full Text] [Related]
37. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib prolongs survival, but what happens to the symptoms?
Strebel BM
J Hepatol; 2012 Jul; 57(1):222-3; author reply 223. PubMed ID: 22342632
[No Abstract] [Full Text] [Related]
39. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth.
Crespo J; Andrade RJ
Rev Esp Enferm Dig; 2019 Oct; 111(10):727-730. PubMed ID: 31566408
[TBL] [Abstract][Full Text] [Related]
40. Apatinib for hepatocellular carcinoma.
Ni Y; Ye X
J Cancer Res Ther; 2019; 15(4):741-742. PubMed ID: 31436225
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]